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Abstract
Background: Since the implementation of the Regulation on Patient Integration (2003), the Act on the
Reorganization of the Pharmaceutical Market (2011), and the Patient Rights Law (2013), the inclusion of patient
perspectives has been further anchored in the German early benefit assessment process. During the assessment of
rare disease interventions, patient perspectives are particularly important, as clinical studies are often designed
acknowledging small samples and patients suffering from severe symptoms and the chronic course of the disease.
Therefore, our research question is whether patient perspectives are considered as part of early benefit assessments
for rare diseases. We also strive to examine how patient perspectives are methodologically elicited and presented.
Methods: Our empirical evidence comes from a systematic review of orphan drug value dossiers submitted to the
German Federal Joint Committee as well as the corresponding evaluations conducted between January 1, 2011 and
March 1, 2019 (n = 81). Data on patient perspective integration were extracted using the following patient-reported
outcome subcategories: clinical patient-reported outcomes, health-related quality of life, patient preferences, and
patient satisfaction.
Results: The analysis demonstrates the specific relevance of patient-reported outcomes raised as part of the medical
data set and presented during the early benefit assessment process. They are predominantly presented in the form of
health-related quality of life data (n = 75%) and clinical outcomes (n = 49%). Preferences (n = 2%) and satisfaction (n =
1%) are still rarely presented, although the heated methodological discussion in Germany would suggest otherwise.
While various methodologies for the integration of clinical outcomes and quality of life data were found, presenting
data on satisfaction and preferences still lacks methodological rigor. The German Federal Joint Committee has not yet
integrated these data in their decision text. Clinical outcomes and quality of life have been included in 46% and 73% of
the cases, respectively.
Conclusions: The underlying analysis demonstrates that there is still a relative high potential for the regular and
systematic inclusion of patient perspectives within the early benefit assessment process for rare diseases. In particular,
patient preferences and patient satisfaction are still rarely included suggesting the need for a clear-cut methodological
foundation and incentives.
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Introduction
The relevance of patient perspective integration in health
care
In Germany, the 2003 Patient Participation Regulation
[1] as well as the 2013 Patient Rights Law [2] form the
most important basis for the integration of patient per-
spectives within the health care system. The Patient Par-
ticipation Regulation, which is linked to §140f of the
German Social Insurance Code Book Volume V, regu-
lates the mandatory involvement of patient organizations
in health care decision making. Within the German Fed-
eral Joint Committee, patient organizations now have
the right to advise and request, but not to vote. In 2013,
patients’ position was further strengthened in terms of
involvement and rights [1, 2].
In the extant literature, patient-oriented health care
systems are created to extend traditional health care
models using patient empowerment. Therefore, import-
ant attributes of patient-oriented health care systems
are identified as: high-quality information generation
and transparency, patient perspective integration
through customization and collaboration, as well as the
integration of patient choice and responsibility. To
these, predictive and preventive instruments can also
be added [3]. Consequently, empirical health economics
have turned towards the collection of evidence regard-
ing patient views. Patients should be effectively inte-
grated during the health technology assessment
process, beginning with evidence generation and value
measurement and concluding with recommendations
and communication of results, e.g., in the context of
health policy [4].
Patient perspectives can be integrated in different
ways. While summarizing data contributed by patients
or their representatives is most common, this approach
must be differentiated from the studies carried out from
the patient perspective but contributing data, for ex-
ample, collected by physicians or other health care spe-
cialists [5]. As a methodologically-grounded approach,
patient-reported outcomes (PRO) stand for the reports
directly originating from patients [5, 6] without the in-
volvement of a physician or other communicators [5].
For instance, Klose et al. [7] report that the terms of
PRO and outcome sometimes diverge in their interpret-
ation. Used as a medical term, an outcome indicates an
end result or intervention consequence in terms of
symptoms and functioning, as well as the health-related
quality of life (HRQoL). However, as reported by the
PRO Harmonization Group, the discussion expanded
from only including HRQoL outcomes to considering
any outcome based on data provided by the patient or
the patient’s proxy [8]. In this study, we follow the
broader interpretation of the term PRO, as provided by
the PRO Harmonization group.
Since the definition of subcategories also varies
broadly, we follow the nomenclature of Klose et al. [7].
This meant that clinical PRO, HRQoL, patient satisfac-
tion, patient experiences, and patient preferences are dif-
ferentiated. Within our analysis, it seemed preferable to
differentiate between the clinical PRO following the
traditional medical interpretation and HRQoL due to
differences in mortality, morbidity, and quality of life
endpoints within the process of early benefit assessment
[2]. Furthermore, patient experiences were not acknowl-
edged separately, as they are predominantly reported in
the context of patient satisfaction and patient prefer-
ences. Preferences describe whether one item is favored
over another [9], meaning they withhold information re-
garding preferable treatment options from the affected
individuals. “Preference” is often used as an umbrella
term. As such, a preference measurement can result in
either utility or value depending on the measurement
approach [10]. There may be various reasons for the
consideration of patient preferences in health care, such
as improved therapy uptake or efficiency of health care
interventions in practice, thus facilitating patient in-
volvement and promoting shared decision-making in
medicine. Medical decisions that are consistent with pa-
tient preferences may facilitate patient acceptance [9, 11,
12]. Therefore, patient satisfaction is also considered an
important component of medical intervention assess-
ments. However, it is a rather subjective assessment of
the quality of care and is often used to incorporate the
patient’s perspective on the quality of care as part of
medical evaluations [12]. Patient satisfaction has not yet
been well defined but is generally considered to describe
a subjective assessment of medical care by patients [13].
Further, the concept can contain various elements such
as medical therapy, nonmedical aspects of treatment, as
well as health care infrastructure [14].
In general, the PRO can be raised via qualitative, mixed,
and quantitative methodologies. Within the field of clin-
ical PROs and HRQoL generic and disease-specific ins-
truments are differentiated by incorporating symptom-
specific modules. Patient preferences can be analyzed
using contingent evaluation approaches, self-explication
approaches, analytic hierarchy process, conjoint analysis,
standard gamble, time trade-off approaches, as well as rat-
ing scales. For the examination of patient satisfaction, vari-
ous approaches exist, such as the Patient Satisfaction
Questionnaire and European Project on Patient Evaluation
of General Practice Care Questionnaire [7].
Patient perspectives in the field of rare diseases
The term “rare diseases” summarizes between 5000 and
8000 different diseases that are characterized by their
severity, by their genetic origin and status as life threat-
ening, or by the chronically debilitating course of the
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disease. Within the European Union, a disease is called
“rare” when fewer than 5 out of 10,000 people are af-
fected. Despite major medical advances in general, a
major unmet medical need has been identified within
the field of rare disease, concerning diagnostic proce-
dures and effective treatment strategies [15]. According
to the German Health Ministry, in Germany alone ap-
proximately 4 million people are affected by rare dis-
eases [16] and although this would seem to suggest that
patient perspectives are particularly important within
the field of rare diseases due to its heterogeneity. There
is still a lack of research on the systematic inclusion of
this field during health economic processes. As demon-
strated by a review of 11 national strategies regarding
patient engagement, the focus of political strategies rests
with the involvement of patient organizations [17]. Ad-
mitting that traditional assessments fail to endorse med-
ical technologies for rare diseases due to a lack of power,
new endpoints have been explored with names such as
Patient-Centered Outcome Measures [18].
Early benefit assessment for rare diseases in Germany
Since the Act on the Reorganization of the Pharmaceut-
ical Market (AMNOG) within the statutory health insur-
ance law issued in December 2010 came into effect in
January 2011, all manufacturers need to provide evi-
dence of the additional benefit of pharmaceutical prod-
ucts claimed over an appropriate comparator. The
German Federal Joint Committee then decides whether
and to what extent a drug can be granted an additional
benefit and their decision forms the basis of price nego-
tiations for the statutory health care setting [19]. Typic-
ally, the Institute for Quality and Efficiency in Health
Care (Institut für Qualität und Wirtschaftlichkeit im
Gesundheitswesen - IQWiG) is engaged to conduct early
benefit assessment, and reports that patient perspectives
play a key role in their judgments. Patient perspectives
are generated using a standardized questionnaire regard-
ing what is important to patients in terms of disease and
treatment strategies [20].
However, in cases of drugs used solely for the treat-
ment of rare diseases (orphan drugs), an additional
benefit is presumed by the European drug approval, au-
thorized in accordance with EC regulation number 141/
2000 on orphan drugs [21]. In such cases, evidence must
only be provided concerning the extent of the additional
benefit to standard therapy for patients [22]. Here, the
IQWiG is not involved in the benefit assessment, but in
the estimation of patient numbers (target group, inci-
dence, prevalence, and trends) as well as treatment costs.
Only when the overall annual treatment costs of an or-
phan drug exceed the limit of 50 million euros for the
statutory health insurance must it pass through the com-
mon early benefit assessment process [23]. Finally,
decision making is taken over by the Federal Joint Com-
mittee, who describe patient involvement as the inclu-
sion of patient representatives and patient organizations
during the process but provide no further description of
the procedure.
Aims of the study
To address this gap, this article examines how the inte-
gration of patient perspectives in the assessment of ben-
efits proceeds. To this end, we examine the development
of a methodologically grounded and direct approach to
patient perspective integration, using the concept of
patient reported outcomes, and analyzing the data sub-
mitted during early benefit assessments for rare diseases
in Germany.
Method
Data sources
Our empirical evidence comes from the database of the
German Federal Joint Committee, withholding all proce-
dures of early benefit assessment induced by §35a
Volume V of the Social Code Book starting with the im-
plementation of the AMNOG law [23]. All procedures
with a starting date of between January 1, 2011 and
March 1, 2019 were considered. In a second step, we fil-
tered for procedures with an orphan drug status and
only procedures marked “completed” were finally
reviewed. Due to the exceeding of the 50-million-euro
boundary or an extension of the area of application,
newly developed active substances can be subject to
multiple assessments.
The Federal Joint Committee makes available the fol-
lowing information on each procedure: the “dossier”
submitted by the pharmaceutical company in accordance
with the modular template, “benefit assessment,” “com-
ments procedure,” and the “resolution” comprising “de-
cisions” as well as the corresponding “rationales” [23].
Data were extracted from the dossier, in particular mod-
ule 4, the benefit assessment, as well as the decision text
developed by the Federal Joint Committee.
Strategy of analysis
To analyze the integration of patient perspectives within
the data set, the PRO concept was used following the
broad definition provided by Black (2003) [6] and Pat-
rick et al. (2003) [5] linked with the nomenclature of
Klose et al. (2016) [7]. Therefore, the following subcat-
egories have been used during the underlying analysis:
 Patient-reported outcomes clinical data (clinical
PROs)
 (Health-related) quality of life (HRQoL)
 Patient preferences
 Patient satisfaction.
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We did not specifically analyze the presented data for
adverse events as HRQoL registers adverse events as well
and mortality captures the fatal adverse events. We par-
ticularly analyzed the data presented within the synopsis
section of the dossiers, the benefit assessment, as well as
the decision text. The respective text passages were
screened particularly searching for terms such as “pa-
tient-reported outcomes,” “quality of life”, “patient pref-
erence” and “patient satisfaction”. The identified sections
were than extracted and transferred to a separate Excel
sheet. Quantitative and qualitative data were reviewed
equally. To provide a first impression on the relevance
of the reported patient perspective within the early bene-
fit assessment of rare diseases, we also examined the
extent of the requested, and later granted, additional
benefit as well as the methodologies actually considered
by the GBA for each PRO data category.
Results
Characteristics of the data sample
Our final sample contained n = 81 value dossiers. The first
dossier was submitted on September 15, 2011 and the last
on September 15, 2018. The different disease groups are
shown in Table 1. A total of 51% of the dossiers within
the field of rare diseases addressed oncological indications,
while metabolic diseases were the second most common,
at 25%.
Benefit assessments were predominantly (n = 71, 88%)
conducted by the Federal Joint Committee itself. The
IQWiG was commissioned with the rare diseases benefit
assessment in 12% (n = 10) of cases, mostly when drugs
were cross-passing the sales limit of 50 million euros
(n = 7). In some cases, the manufacturer applied for an
additional application area (n = 3). It should be noted
that, whereas all agents cross passing the 50 million euro
limit were commissioned to the IQWiG, applications for
additional application areas were also assessed by the
GBA itself.
Table 2 shows the benefit scores that were applied for
by the pharmaceutical companies during those pro-
cesses, as well as the GBA score granted by the Federal
Joint Committee. Applied and granted benefit scores
matched in 19% of cases. No additional benefit was de-
termined in 2% of cases as part of a reassessment after
the trespassing of the 50 million Euro limit conducted
by the IQWiG.
Analysis
Table 3 shows a summary of the analysis of patient-
reported data during the early benefit assessment process
for rare diseases.
PROs are mostly presented in the form of self-
reported clinical outcomes data (n = 39, 48%) followed
by data on HRQoL (n = 61, 75%). Data on patient prefer-
ences were included twice (2%) and on patient satisfac-
tion only once (1%). In only 15% (n = 12) of cases, no
data on PROs were submitted. Therefore, data on PROs
were presented to a relatively high extent. In 85% of
cases, PROs were presented from at least one PRO sub-
category. The Federal Joint Committee considered clin-
ical PRO data in 37 (46%) cases, whereas HRQoL data
were included in 59 (73%) cases. Patient satisfaction and
patient preferences were not included within the deci-
sion text. Another example, which was often considered
as part of the GBA decision text (n = 13), was the
EORTC (Core Quality of Life Questionnaire). The split-
ting of the questionnaire items into clinical PROs and
QoL PROs could also be observed here.
Table 4 shows the overall number of assessment pro-
cesses for each year since the implementation of the
AMNOG law. In 2017, 16 processes were initiated. Twelve
processes presented data on Clinical PROs, 13 processes
withheld HRQoL data, and 1 process presented data on
Table 1 Disease groups covered by the rare diseases benefit assessment procedures
Disease groups Number Percentage
Diseases of the eyes 2 2%
Cardiovascular diseases 3 4%
Infectious diseases 1 1%
Diseases of the digestive system 4 5%
Diseases of the respiratory tract 2 2%
Diseases of the blood and the blood-forming tissues 2 2%
Diseases of the musculoskeletal system 2 2%
Diseases of the nervous system 3 4%
Oncological diseases 41 51%
Metabolic diseases 20 25%
Other 1 1%
Sum =81 =100%
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preferences. Overall, the direct integration of patient per-
spectives in the form of PROs has gradually increased in
its absolute number, with an increased number of induced
processes since the implementation of the AMNOG law
in 2011. Regarding the relative percentage of PROs in rela-
tion to the number of processes included within our ana-
lysis, no clear-cut trend is observable.
Analyzing the clinical PRO and HRQoL data, it was
observable that the GBA split the surveys into symptom
scales (clinical PRO data listed as part of the morbidity
endpoints) and HRQoL scales. An example is the oncol-
ogy specific EORTC QLQ-C30. In this context, the EQ-
5D VAS scale has been categorized as part of the mor-
bidity section. However, the EQ-5D Index has been ap-
preciated as part of the HRQoL section. Moreover,
further commonly acknowledged methodologies were
the childhood health questionnaires and the Brief Pain
Inventory (BPI) as well as the Functional Assessment of
Chronic Illness Therapy - Fatigue (FACIT-F). On the
other hand, commonly acknowledged HRQoL method-
ologies included disease-specific FACT-questionnaires,
SF-questionnaires, and the Pediatric Quality of Life in-
ventory (PedsQL).
The heatedly discussed categories “patient satisfaction”
and “patient preferences” were rarely referred to, and
when they were, it was in a qualitative manner [24–26].
Quantitative methods were not used. The dossier sub-
mitted for the agent Velmanase alfa (2018) offered “pa-
tient cases” in the form of short summaries, backing
clinical PROs as well as the relevance of symptoms
(preferences) and overall quality of life (not naming
HRQoL in this case). There was no description of the
detailed qualitative research strategy. Telotristatethyl
(2017) provided “semi-structured telephone-interviews”
on topics such as symptom description, preferences, and
patient experiences. Some structural background data
were provided, but again no description of the qualita-
tive research strategy was included. In the case of Eftre-
nonacog alfa (2016), during a first phase, “focus groups”
were cited as well as a “structured questioning” that also
considered satisfaction. Results were presented in a
qualitative manner but there was no solid description of
the qualitative research strategy. Patient satisfaction and
patient preferences were not included at all within the
GBA decision body, thus providing no incentives for fur-
ther data presentation. A detailed overview of the data
can be found in Table 5.
Discussion
Summary of findings
The present study analyzes data on the direct involve-
ment of the patient perspective, particularly in the form
of PROs, which are submitted, evaluated, and considered
during the early benefit assessment process for rare dis-
eases in Germany. The results demonstrate that patient
perspectives predominantly enter the process via clinical
PROs and HRQoL. However, in comparison with clinical
PRO and HRQoL, the categories “patient satisfaction”
and “patient preferences” were rarely referred to, and if
they were, it was in a qualitative manner that lacked a
solid description of the methodological foundation
within qualitative research. Nevertheless, we found that
16% of the orphan drug dossiers did not present any
data on PROs.
Significance in the context of literature
To our knowledge, this study provides unique insights
into the inclusion of patient perspectives within the early
benefit analysis process, in particular using PROs as part
of the early benefit assessment of orphan drugs.
Braithwaite et al. [27] highlight again the importance of
PROs in the field of rare diseases since some of the
methods used in this field of research permit smaller sam-
ple sizes. They also pinpoint the importance of primary
outcome measures in general and that, in particular, trad-
itional outcome measures have failed to demonstrate effi-
ciency. While considerable progress has been made in the
development of associated measures, it is still difficult to
find tools for less common indications [27]. This may be
one of the explanations for low acceptance and / or sub-
mission of PROs in the field of rare diseases.
Table 2 Benefit score of the orphan drug benefit assessment processes
Data analysis Number of events (n) Percentage of overall data% Number of events (n) Percentage of overall data%
Benefit score Applied Granted
Major 45 56% 10 12%
Considerable 21 26% 0 0%
Minor 4 5% 20 25%
Not quantifiable 11 14% 49 60%
No additional benefit – – 2 2%
Comparison
Matching benefit scores 15 19% – –
In some cases, patient populations were separated. In these cases, we solely considered the highest attained score
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control Changes within the political framework can
affect pharmaceutical companies’ submission behavior.
For example, before the introduction of the Patient
Rights Law in 2013 [2], only three dossiers were
submitted, while afterwards, the number of dossiers for
orphan drugs increased to approximately 16 per year.
However, the data cannot capture the possible impacts
of changes in legislation since these events occur at a
Table 3 Submission and consideration of PROs as part of the early benefit assessment process of rare diseases
Category Number of PRO data sets (n) Percentage of events in relation to overall number of processes (%)
Industry – type of PRO data submitted (module 4)
Clinical PROs 41 51%
HRQoL 61 75%
Preferences 2 2%
Satisfaction 1 1%
Industry - extent of PRO data submitted (module 4)
No PRO data submitted 13 16%
Data on one PRO category 35 43%
Data on two PRO categories 31 38%
Data on three PRO categories 2 2%
Early benefit assessment – type of PRO data considered in synopsis
Clinical PRO 39 48%
HRQoL 58 72%
Preferences 0 0%
Satisfaction 0 0%
Early benefit assessment – extent of PRO data submitted
No PRO data considered 43 53%
One PRO category 63 78%
Two PRO categories 54 67%
Three PRO categories 2 2%
GBA decision – extent of PRO data considered in the decision
No PRO data considered 31 38%
One PRO category 25 31%
Two PRO categories 25 31%
Three PRO categories 0 0%
GBA decision – type of PRO data considered in the decision
Clinical PROs 39 48%
HRQoL 59 73%
Preferences 0 0%
Satisfaction 0 0%
Comparison between data submitted and data considered by the GBA
Identical number of PRO categoriesa 42 50%
Diverging number of PRO categoriesa 29 40%
Clinical PROs - not considered by GBA 8 21%
Clinical PROs - added by GBA 6 15%
HRQoL - not considered by GBA 19 31%
HRQoL – added in GBA decision 2 3%
Preferences – not considered by GBA 2 100%
Satisfaction – not considered by GBA 1 100%
GBA German Federal Joint Committee, HRQoL Health Related Quality of Life, PRO Patient-reported Outcomes. aThe number does not add up to n = 81 (all
regarded processes) as some manufacturers did not provide PRO data
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small rate and could be falsified by the overall orphan
drug submission rate.
Furthermore, the methodological developments within
the health economic environment in Germany can also
influence the development of data submission and its
appraisal. In 2013, the IQWiG discussed changes to its
methodology for the very first time. Institutes and indus-
trial representatives argued for the direct, transparent,
and systematic integration of patient perspectives, in
particular patient preferences and the definition of the
precise integration processes [24]. In 2015, another dis-
cussion of the IQWiG general methods paper was pub-
lished. However, the focus of the discussion concerning
patient perspectives integration was predominantly in re-
lation to the reintegration of patient satisfaction as op-
tional data [25]. Moreover, in 2017, the last recorded
methodological discussion was published and, in this
context, the systematic direct integration of patient per-
spectives was again demanded in several parts of the
IQWiG methods paper, e.g., the clear-cut acknowledge-
ment of patient preferences [26]. The first pilot projects
concerning the measurement and inclusion of patient
preferences in health economic evaluation were pub-
lished in 2013 (Analytic Hierarchy Process (AHP) [28,
29] and 2014 (Conjoint Analysis) [30, 31]. Although the
named projects and discussions seem to lay the basis for
the methodologically grounded inclusion of patient per-
spectives, the first inclusions of patient preferences were
recorded in 2017 and 2018 in the field of rare diseases.
However, since many of the above-named quantitative
methods are not appropriate in the field of rare diseases
due to the limitation of small sample sizes (see also [18])
(an exception is the AHP [32, 33]), further specified re-
quirements for qualitative data presentation are re-
quired, as well as incentives for their adaptation. The
same arguments hold for patient satisfaction, which is
referred to as additional submittable data but in its
patient-centeredness is relevant by definition.
Clinical patient-reported outcomes and health related
quality of life
Furthermore, in terms of particular relevance, it has been
argued that the documentation of clinical PROs - for ex-
ample, as part of the phenotype “pain” - offers the chance
to better align treatment options and outcomes [34].
Casamayor et al. [35] analyzed whether PROs in on-
cology matter in health technology assessments con-
ducted in Germany, France, and the UK, and found that
an improvement in such outcomes did not increase the
chance of a positive health technology assessment
(HTA) recommendation. The authors also demonstrated
that PROs assessing Quality of Life (51/57, 89.4%) and
pain measures (18/57, 31.6%) are the most common.
PROs were not mentioned at all in 35.1% of cases [35].
Although our analysis examines HRQoL measures and
morbidity-focused clinical PROs, the tendencies of both
research papers seem to be similar. An early stage ana-
lysis of the first 25 dossiers in Germany regarded inde-
pendently of the targeted indication demonstrated that
in the beginning HRQoL outcomes were not considered
during the early benefit process for different reasons [36,
37]. In our analysis, we found that this category was the
most acceptable for the Joint Federal Committee. How-
ever, the general position of the Federal Joint Committee
on the importance of quality of life data has changed sig-
nificantly in the last 10 years. Initially rated as support-
ing or complementary information, quality of life data is
today accounted equivalent to endpoints of mortality
and morbidity [38]. Nevertheless, there are methodo-
logical questions regarding measurement and distinction
that are not yet clear.
Patient preferences
The proportion of dossiers including data on patient pref-
erences was quite low. Obradovic and Rauland [39] state
that approximately 25% of all dossiers published between
2011 and 2014 referred to some extent to patient prefer-
ences. However, the database used seems to be more
broadly designed. In the case of the present study, we in-
cluded data from the as by the pharmaceutical company
submitted studies but this also prompts further research
questions regarding the differences between the integra-
tion of patient perspectives in the field of rare diseases and
other indications. Of course, many quantitative measure-
ment methods such as choice experiments/conjoint ana-
lyses are hardly feasible in the field of rare diseases.
Furthermore, their specific aim is to compare different
treatment methods (trade-off), which are often not pro-
vided in the field of rare diseases.
Table 4 Development of PRO data submissions for rare diseases over time
Items 2018 2017 2016 2015 2014 2013 2012 2011
Assessment processes 10 16 17 15 13 3 5 2
Clinical PROs 4 40% 12 75% 11 65% 6 40% 4 31% 0 0% 0 0% 0 0%
HRQoL 6 60% 13 81% 13 76% 11 73% 10 77% 2 67% 4 80% 2 100%
Preferences 1 10% 1 6% 0 0% 0 0% 0 0% 0 0% 0 0% 0 0%
Satisfaction 0 0% 0 0% 1 6% 0 0% 0 0% 0 0% 0 0% 0 0%
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Although we controlled for incentives to render data
on patient perspectives in a direct and systematic way
considering PROs, it must also be stated that there are
some factors outside the set framework that may also in-
fluence the presentation of data. For example, the benefit
score and associated documents form the basis for price
negotiation in Germany [40, 41].
Besides, the methodological foundation for patient
preferences has also been developed in an international
context and substantial literature has been published.
The International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) developed a good research
practice checklist for conjoint-analysis in health.
The checklist included 10 items covering the research
question, levels and attributes, task development, the de-
sign of the experiment, preference elicitation, design of
instruments, data-collection, analyzing statistical data,
results and conclusions as well as study presentation
standards. Even though, not endorsing a specific meth-
odological approach, the checklist can serve as a good
foundation for further discussions of good research prac-
tice for the application of conjoint-analysis methods in
health care studies [42]. Besides, further research efforts
give in depth advice concerning specific elements of the
research process, for example the experimental design
[43]. Several studies review the usage of different meth-
odologies raising patient preferences systematically for
different indications such as for example diabetes [44,
45]. Further, CONSORT guidelines advise on the report-
ing of PRO data in general [46]. This study contributed
to the existing literature by outlining the methodology
of PRO data inclusion within the field of rare diseases in
Germany.
Limitations
In terms of limitations, data on clinical PROs could only
be identified as such as long as they were highlighted as
a self-reported measure or indicated to be a patient-
reported measure. When no particular definition was
provided, we assumed that the endpoint was physician-
reported. We assume that almost all endpoints were spe-
cifically marked as patient-reported, as dossier providers
have often argued that clinical PROs are particularly
relevant to the patient and should therefore be specific-
ally considered during the valuation and decision-
making process. Furthermore, PROs are clearly defined
as self-reported. However, in the case of clinical PROs,
the reporting system was sometimes not indicated. In
these cases, we searched for the primary classification of
the symptoms scale.
In addition, pharmaceutical companies present their
HRQoL data as a whole data subset. However, the Federal
Joint Committee separates parts of the questionnaires se-
lectively regarding mortality endpoints and HRQoL
endpoints. Therefore, the data reveal a splitting of the
datasets rendered by the pharmaceutical company. End-
points were not shifted as this would not reflect the actual
status quo of the data presented but would, rather, lead
eventually to a presentation bias. However, it needs to be
highlighted as a specific procedure presented by the Ger-
man Federal Joint Committee and considered when
selecting the appropriate data presentation technique.
Finally, it needs to be highlighted that some dossiers
can fail due to formal reasons, for example not the
appropriate comparator, a study population narrower
than label etc. Therefore, the impact of PROs on the
final decision is not always directly derivable.
Conclusions
The underlying evaluation demonstrates that although
the political basis has been strengthened and the pre-
sented concepts have been broadly laid out as part of
the health economic discussion in the context of benefit
analysis and cost-benefit analysis, there remains a broad
potential for the development of the practical framework
regarding the systematic inclusion of patient perspec-
tives, especially in referring to patient preferences and
patient satisfaction, particularly considering the example
of early benefit assessments for rare diseases in
Germany. In this regard, it is interesting that patient
preferences are presented in a qualitative manner. The
broadly discussed and exemplified (by the IQWiG)
quantitative methods have not been demonstrated in the
field of rare diseases to date. While methodological stan-
dards for qualitative reporting have not yet been
adopted, they must be appreciated with the same thor-
oughness as within quantitative research settings. An ac-
cording clarification of the standard guidelines needs to
be demanded. Moving even one step ahead, potentials of
the integration of qualitative and quantitative research
may be discussed, appreciated, and scientifically moni-
tored in this specific context. Furthermore, the interim
radiation of patient satisfaction has been commented on
with vehement protest. In practice, however, it is only
presented in 2% of cases in the field of rare diseases,
even though this topic seems highly relevant due to the
predominantly chronic and severe course of diseases.
Neither of the PRO categories are enlisted within the
GBA decision text. Acknowledged clinical PROs are
often raised by the BPI-SF (pain scale) and FACIT-F (fa-
tigue index). On the other hand, FACT-questionnaires,
SF-questionnaires, and PedsQL are often GBA-
appreciated HRQoL PROs. It is noteworthy that HRQoL
questionnaires are in many cases split with regard to
morbidity and HRQoL items, as datasets produced by
one questionnaire are submitted cohesively. In this re-
gard, the EQ-5D VAS is often appreciated as a morbidity
endpoint by the GBA and therefore, in this context, it is
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categorized as a clinical PRO, whereas the EQ-5D-Index
is categorized as a HRQoL. Another commonly accepted
example is the oncology indication specific EORTC
QLQ-C30. This may lead to irritation, hindering the
preparation of PRO data inclusion by pharmaceutical
companies. Therefore, potential implications should be
clarified.
Furthermore, the extent of PRO data presentation
withholds considerable potentials. It is questionable
whether morbidity-oriented clinical PROs should only
be included in every second dossier, when it is highly
relevant to the patient and to treatment success. Patient
satisfaction and patient preferences follow by the same
token. Appreciating the central role of patient perspec-
tives within early benefit assessments and the according
legal framework, the GBA decision text should particu-
larly appreciate the consideration of patient perspectives,
flagging incentives for more extensive consideration.
Considering the growing financial pressure on health
care systems, strengthening direct patient perspective in-
volvement by further integrating PROs holds an im-
mense opportunity to align health care with actual
patient needs and therefore to contribute to an effective
and needs-oriented health care system development.
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